Plus Therapeutics has begun treating the first patients in its ReSPECT-LM dose optimization trial for REYOBIQ™, a targeted radiotherapeutic designed for leptomeningeal metastases (LM). This trial follows a successful Phase 1 study, which demonstrated the treatment’s feasibility, and aims to determine the optimal dosing regimen for maximum efficacy and safety, aligning with the FDA’s Project Optimus. The company anticipates rapid enrollment due to promising Phase 1 results and the unmet medical need for effective LM treatments.
This trial is crucial because LM, a complication of advanced cancers affecting the central nervous system, currently lacks effective FDA-approved therapies. The initial Phase 1 results, showcasing an over 80% reduction in LM tumor cells in some patients’ cerebrospinal fluid and increased survival rates, suggest that REYOBIQ™ could address this critical gap and significantly improve patient outcomes. This development holds substantial promise for patients facing this aggressive form of cancer, offering a potential lifeline where few options currently exist.
The ReSPECT-LM trial, supported by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT), is designed to determine the safety and tolerability of multiple REYOBIQ™ doses administered via intraventricular catheter. The research will establish both the maximum tolerated dose and the minimum effective dose, vital information for maximizing therapeutic benefit while minimizing adverse effects. Plus Therapeutics will present data from the completed single-dose escalation trial at the upcoming SNO/ASCO CNS Metastases Conference and will request an End of Phase 1 Type B meeting with the FDA to discuss the clinical development plan and a potential registrational trial design.
The initiation of this dose optimization trial marks a significant step forward in the development of REYOBIQ™ as a potentially game-changing treatment for LM. Positive results could lead to an accelerated regulatory pathway and ultimately provide a much-needed, effective therapy for patients with this devastating condition. This development also underscores the growing potential of targeted radiotherapeutics in addressing complex cancers and improving outcomes in areas with limited treatment options.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
